Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
NS Vasudev, AR Reynolds - Angiogenesis, 2014 - Springer
Tumours require a vascular supply to grow and can achieve this via the expression of pro-
angiogenic growth factors, including members of the vascular endothelial growth factor …
angiogenic growth factors, including members of the vascular endothelial growth factor …
CT perfusion in oncologic imaging: a useful tool?
R García-Figueiras, VJ Goh… - American Journal of …, 2013 - Am Roentgen Ray Soc
OBJECTIVE. This article summarizes the current status of CT perfusion in oncologic
imaging, including lesion characterization, staging, prediction of patient outcome or …
imaging, including lesion characterization, staging, prediction of patient outcome or …
Metastatic renal cell carcinoma: radiologic findings and assessment of response to targeted antiangiogenic therapy by using multidetector CT
BP Brufau, CS Cerqueda, LB Villalba, RS Izquierdo… - Radiographics, 2013 - pubs.rsna.org
Recent advances in treatment of metastatic renal cell carcinoma (RCC), such as new
molecular therapies that use novel antiangiogenic agents, have led to revision of the most …
molecular therapies that use novel antiangiogenic agents, have led to revision of the most …
Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib
LM Riesenbeck, S Bierer, I Hoffmeister, T Köpke… - World journal of …, 2011 - Springer
Purpose To investigate prognostic markers in patients with metastatic renal cell carcinoma
(mRCC) undergoing treatment with the tyrosine kinase inhibitors (TKIs) sorafenib (So) or …
(mRCC) undergoing treatment with the tyrosine kinase inhibitors (TKIs) sorafenib (So) or …
Imaging biomarkers for evaluating tumor response: RECIST and beyond
CC Ko, LR Yeh, YT Kuo, JH Chen - Biomarker research, 2021 - Springer
Abstract Response Evaluation Criteria in Solid Tumors (RECIST) is the gold standard for
assessment of treatment response in solid tumors. Morphologic change of tumor size …
assessment of treatment response in solid tumors. Morphologic change of tumor size …
[HTML][HTML] Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and …
J Bellmunt, JL Gonzalez-Larriba, C Prior, P Maroto… - Annals of oncology, 2011 - Elsevier
Background A strong rationale supports the role of antiangiogenic drugs in urothelial cancer.
This trial was designed to assess the activity of sunitinib as first-line treatment in patients …
This trial was designed to assess the activity of sunitinib as first-line treatment in patients …
Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing …
BACKGROUND: Vascular endothelial growth factor (VEGF)-targeted therapy has become
standard treatment for patients with metastatic renal cell cancer (mRCC). Since these …
standard treatment for patients with metastatic renal cell cancer (mRCC). Since these …
Predictive biomarkers in renal cell cancer: insights in drug resistance mechanisms
JC van der Mijn, JW Mier, HJ Broxterman… - Drug Resistance …, 2014 - Elsevier
Introduction VEGF-targeted therapy is currently the first line treatment for patients with
metastatic clear cell renal cell carcinoma (ccRCC), but most patients either display primary …
metastatic clear cell renal cell carcinoma (ccRCC), but most patients either display primary …
Prognostic value of 18F‐FDG PET for hepatocellular carcinoma patients treated with sorafenib
Abstract Background: Sorafenib (Nexavar) is an orally active multikinase inhibitor that is
approved for the treatment of hepatocellular carcinoma (HCC). In this study, we used 18F‐2 …
approved for the treatment of hepatocellular carcinoma (HCC). In this study, we used 18F‐2 …
[PDF][PDF] Current status of targeted therapy for advanced renal cell carcinoma
IC Cho, J Chung - Korean journal of urology, 2012 - synapse.koreamed.org
The treatment of metastatic renal cell carcinoma (mRCC) has recently evolved from being
predominantly cytokine-based treatment to the use of targeted agents, which include …
predominantly cytokine-based treatment to the use of targeted agents, which include …